Galectin Therapeutics (GALT) Misses Q2 EPS by 1c

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
• Worthington Industries (WOR) Tops Q1 EPS by 7c